{
  "meta": {
    "timestamp": "2025-01-06T09:08:56.598279",
    "version": "1.0",
    "type": "search_analysis"
  },
  "companies": [
    {
      "company_name": "Dyne Therapeutics Inc",
      "symbol": "DYN",
      "analysis": {
        "historical": {
          "risk_score": 70,
          "key_risks": [
            "Clinical trial risks: Lead candidates DYNE-101 and DYNE-251 are in early-stage trials with significant risk of failure in later stages.",
            "Regulatory hurdles: FDA clinical hold on DYNE-251 and potential additional requirements for DYNE-101 could delay or prevent approval.",
            "Financial sustainability: Heavy reliance on external funding; future financing challenges could jeopardize R&D activities.",
            "Competition: Highly competitive rare muscle disease space with multiple companies developing treatments."
          ],
          "controversies": [
            "FDA clinical hold on DYNE-251 due to requests for additional clinical and non-clinical data."
          ],
          "environmental_issues": [],
          "social_issues": [
            "Patient-centric approach: Engagement with patient advocacy groups and individuals living with rare muscle diseases to design clinical trials."
          ],
          "governance_issues": [],
          "recommendation": "caution",
          "confidence_score": 80
        },
        "evidence": {
          "sources": [
            {
              "url": "",
              "title": "Clinical Trials - Dyne Therapeutics",
              "snippet": "The ACHIEVE trial is a Phase 1/2 global clinical trial evaluating DYNE-101, consisting of a 24-week multiple ascending dose-randomized placebo-controlled period, a 24-week open-label extension (OLE) period and a 96-week long-term extension (LTE) period. ... If you have questions about Dyne Therapeutics' clinical trials, please contact us at ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Dyne Therapeutics Inc Dyne Therapeutics Inc clinical trial failures",
              "retrieved_at": "2025-01-06T16:08:25.172914+00:00",
              "published_date": null,
              "source_hash": "0e31dea49ef869944a40139a87c999dc"
            },
            {
              "url": "",
              "title": "Dyne Therapeutics Announces Positive Initial Clinical Data from ACHIEVE ...",
              "snippet": "ACHIEVE is a Phase 1/2 global clinical trial evaluating DYNE-101, consisting of a 24-week multiple ascending dose (MAD) randomized placebo-controlled period, a 24-week open-label extension and a 96-week long-term extension. ... About Dyne Therapeutics. Dyne Therapeutics is a clinical-stage muscle disease company focused on advancing innovative ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Dyne Therapeutics Inc Dyne Therapeutics Inc clinical trial failures",
              "retrieved_at": "2025-01-06T16:08:25.173028+00:00",
              "published_date": null,
              "source_hash": "4c659edc9cca05eec7b678a50482fa4f"
            },
            {
              "url": "",
              "title": "Dyne Therapeutics, Inc. - Drug pipelines, Patents, Clinical trials ...",
              "snippet": "WALTHAM, Mass., Sept. 23, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that management is scheduled to participate in a fireside chat at Chardan's 8th ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Dyne Therapeutics Inc Dyne Therapeutics Inc clinical trial failures",
              "retrieved_at": "2025-01-06T16:08:25.173046+00:00",
              "published_date": null,
              "source_hash": "7a003102147eb5b23cd1fe5d6d6bd1d9"
            },
            {
              "url": "",
              "title": "Dyne Therapeutics Reports Second Quarter 2024 Financial Results and ...",
              "snippet": "In May 2024, Dyne reported positive clinical data from the ongoing DELIVER trial of DYNE-251 in patients with DMD amenable to exon 51 skipping. Efficacy data were based on 8 male patients with DMD enrolled in the 10 mg/kg (approximate PMO dose) cohort of the DELIVER trial. 10 mg/kg of DYNE-251 Q4W demonstrated dose-dependent exon skipping and ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Dyne Therapeutics Inc Dyne Therapeutics Inc clinical trial failures",
              "retrieved_at": "2025-01-06T16:08:25.173059+00:00",
              "published_date": null,
              "source_hash": "38b6b9c353413fd6d0a429e0aba93f5f"
            },
            {
              "url": "",
              "title": "Dyne Therapeutics Announces New Clinical Data from ACHIEVE Trial of ...",
              "snippet": "--Dyne Therapeutics, Inc., a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Dyne Therapeutics Inc Dyne Therapeutics Inc clinical trial failures",
              "retrieved_at": "2025-01-06T16:08:25.173069+00:00",
              "published_date": null,
              "source_hash": "9f89aa4d20ab99007e99b494387c8876"
            },
            {
              "url": "",
              "title": "Genetic Medicines Biotech Dyne Pulls In $345M for Clinical Tests of ...",
              "snippet": "Dyne Therapeutics recently reported encouraging Phase 1/2 clinical data in myotonic dystrophy type 1 and Duchenne muscular dystrophy. At the J.P. Morgan Healthcare Conference, CEO Joshua Brumm ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Dyne Therapeutics Inc Dyne Therapeutics Inc clinical trial failures",
              "retrieved_at": "2025-01-06T16:08:25.173080+00:00",
              "published_date": null,
              "source_hash": "e67f8b4c53b8f72f12c069ec7366ced8"
            },
            {
              "url": "",
              "title": "Dyne Therapeutics Announces Initiation of Phase 1/2 ACHIEVE Clinical ...",
              "snippet": "WALTHAM, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced the initiation of its ACHIEVE Phase 1/2 clinical trial evaluating DYNE-101 for the ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Dyne Therapeutics Inc Dyne Therapeutics Inc clinical trial failures",
              "retrieved_at": "2025-01-06T16:08:25.173089+00:00",
              "published_date": null,
              "source_hash": "c32654cebd837f84ad877eef2c006679"
            },
            {
              "url": "",
              "title": "Dyne Therapeutics Receives FDA Orphan Drug Designation for DYNE-101 for ...",
              "snippet": "Dyne Therapeutics, Inc. - On Track to Report Initial Data from the Global, Multiple Ascending Dose Phase 1/2 ACHIEVE Clinical Trial in the Second Half of 2023 -",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Dyne Therapeutics Inc Dyne Therapeutics Inc clinical trial failures",
              "retrieved_at": "2025-01-06T16:08:25.173099+00:00",
              "published_date": null,
              "source_hash": "f014c0e86782864dd3daf1fc2710872d"
            },
            {
              "url": "",
              "title": "Dyne Therapeutics Announces FDA Lifts Clinical Hold for DYNE-251",
              "snippet": "- Initiation of Dosing in Multiple Ascending Dose Clinical Trial in Patients with Mutations Amenable to Skipping Exon 51 On Track for Mid-2022 - WALTHAM, Mass., July 05, 2022 (GLOBE NEWSWIRE) \u2014 Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Dyne Therapeutics Inc Dyne Therapeutics Inc patient advocacy controversies",
              "retrieved_at": "2025-01-06T16:08:35.289125+00:00",
              "published_date": null,
              "source_hash": "c0a32e87c04c7a3bd15692a21c119e37"
            },
            {
              "url": "",
              "title": "Dyne Therapeutics Reports Positive Data From Phase 1/2 DELIVER Trial Of ...",
              "snippet": "(RTTNews) - Tuesday, Dyne Therapeutics, Inc. (DYN) revealed new clinical findings from its Phase 1/2 DELIVER trial of DYNE-251 for patients with Duchenne muscular dystrophy also known as DMD.",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Dyne Therapeutics Inc Dyne Therapeutics Inc clinical trial failures",
              "retrieved_at": "2025-01-06T16:08:25.173124+00:00",
              "published_date": null,
              "source_hash": "7d0b18b352152225a95b7c2e62aeaf91"
            },
            {
              "url": "",
              "title": "Genetic Medicines Biotech Dyne Pulls In $345M for Clinical Tests of Muscle Drugs",
              "snippet": "Dyne Therapeutics started the new year with proof-of-concept clinical data for experimental genetic medicines addressing two rare muscle diseases\u2014one of which has no FDA-approved treatments.",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Dyne Therapeutics Inc Dyne Therapeutics Inc clinical trial failures",
              "retrieved_at": "2025-01-06T16:08:27.808052+00:00",
              "published_date": "2024-01-15T00:00:00+00:00",
              "source_hash": "eb028da80a7c86b9185e26aceca70412"
            },
            {
              "url": "",
              "title": "Dyne Therapeutics Reveals Q3 Results and Trial Updates",
              "snippet": "Dyne Therapeutics, Inc. ( (DYN)) has released its Q3 earnings ... Dyne Therapeutics highlighted significant progress in its clinical trials and substantial financial resources.",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Dyne Therapeutics Inc Dyne Therapeutics Inc clinical trial failures",
              "retrieved_at": "2025-01-06T16:08:27.808087+00:00",
              "published_date": "2024-11-14T08:45:00+00:00",
              "source_hash": "02f34048bd1cb24e4a17423e8d817050"
            },
            {
              "url": "",
              "title": "Dyne Therapeutics, Inc. (NASDAQ:DYN) Shares Acquired by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC",
              "snippet": "Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States.",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Dyne Therapeutics Inc Dyne Therapeutics Inc clinical trial failures",
              "retrieved_at": "2025-01-06T16:08:27.808096+00:00",
              "published_date": "2024-12-12T00:00:00+00:00",
              "source_hash": "509c31d39f12c46f7066225616a4d588"
            },
            {
              "url": "",
              "title": "Drug Developer Dyne Therapeutics Weigh Options After Takeover Interest",
              "snippet": "(Bloomberg) -- Dyne Therapeutics Inc. shares surged more than 40% after ... two drugs \u2014 known as DYNE-101 and DYNE-251 \u2014 in clinical trials, according to its website. It's likely to attract ...",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Dyne Therapeutics Inc Dyne Therapeutics Inc clinical trial failures",
              "retrieved_at": "2025-01-06T16:08:27.808103+00:00",
              "published_date": "2024-01-26T20:57:00+00:00",
              "source_hash": "e9f9a25b0e3e8649e3b3e401578f7fbf"
            },
            {
              "url": "",
              "title": "Dyne Therapeutics (NASDAQ:DYN) Shares Gap Up - Still a Buy?",
              "snippet": "Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States.",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Dyne Therapeutics Inc Dyne Therapeutics Inc clinical trial failures",
              "retrieved_at": "2025-01-06T16:08:27.808110+00:00",
              "published_date": "2024-12-15T00:00:00+00:00",
              "source_hash": "e42b850d38c83bbb5a97f32beb6b5ce5"
            },
            {
              "url": "",
              "title": "10-K - SEC.gov",
              "snippet": "Dyne Therapeutics, Inc. ... and Drug Administration has placed the investigational new drug application for our planned Phase 1/2 clinical trial of DYNE-251 on clinical hold and requested that we submit additional clinical and non-clinical information for DYNE-251. ... such side effects or properties could delay or prevent regulatory approval ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Dyne Therapeutics Inc Dyne Therapeutics Inc regulatory approval delays",
              "retrieved_at": "2025-01-06T16:08:31.396677+00:00",
              "published_date": null,
              "source_hash": "dd5a09864dd10b0b3ba0aa744afaf45d"
            },
            {
              "url": "",
              "title": "Dyne Therapeutics Reports Third Quarter 2024 Financial Results and ...",
              "snippet": "Dyne Therapeutics, Inc. - IND Application for DYNE-101 for DM1 Cleared by FDA - - New Clinical Data from DYNE-101 ACHIEVE Trial Expected in Early January 2025 -",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Dyne Therapeutics Inc Dyne Therapeutics Inc regulatory approval delays",
              "retrieved_at": "2025-01-06T16:08:31.396738+00:00",
              "published_date": null,
              "source_hash": "a9943470c0b2a149c4bf3a7afb323504"
            },
            {
              "url": "",
              "title": "Dyne Therapeutics Receives FDA Fast Track Designation for DYNE-251 for ...",
              "snippet": "WALTHAM, Mass., Oct. 31, 2022 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Dyne Therapeutics Inc Dyne Therapeutics Inc patient advocacy controversies",
              "retrieved_at": "2025-01-06T16:08:35.289142+00:00",
              "published_date": null,
              "source_hash": "d27660d280b30fb9414d0820d331bd3f"
            },
            {
              "url": "",
              "title": "Dyne Therapeutics Announces FDA Clearance of IND Application for DYNE ...",
              "snippet": "Dyne Therapeutics Announces FDA Clearance of IND Application for DYNE-251 for the Treatment of Duchenne Muscular Dystrophy Dyne Therapeutics, Inc. Tue, Jul 5, 2022, 7:30 AM 6 min read",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Dyne Therapeutics Inc Dyne Therapeutics Inc regulatory approval delays",
              "retrieved_at": "2025-01-06T16:08:31.396763+00:00",
              "published_date": null,
              "source_hash": "e7a0a64295be3319582558578b3189b2"
            },
            {
              "url": "",
              "title": "Dyne Therapeutics, Inc. SEC 10-Q Report \u2014 TradingView News",
              "snippet": "Dyne Therapeutics, Inc., a biotechnology company focused on developing muscle disease therapeutics, has released its Form 10-Q report for the quarter ended September 30, 2024. ... or failure to demonstrate safety and efficacy could prevent or delay regulatory approval and commercialization. Commercialization Risks: ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Dyne Therapeutics Inc Dyne Therapeutics Inc regulatory approval delays",
              "retrieved_at": "2025-01-06T16:08:31.396773+00:00",
              "published_date": null,
              "source_hash": "e5482ef60586273752a0b19ddea3ebad"
            },
            {
              "url": "",
              "title": "Dyne Therapeutics, Inc. (Form: S-1/A, Received: 09/10/2020 07:02:49)",
              "snippet": "Dyne Therapeutics, Inc. 830 Winter Street . Waltham, Massachusetts 02451 (781) 786-8230 (Name, address, including zip code, and telephone number, including area code, of agent for service) ... , such side effects or properties could delay or prevent regulatory approval, limit the commercial potential or result in significant negative ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Dyne Therapeutics Inc Dyne Therapeutics Inc regulatory approval delays",
              "retrieved_at": "2025-01-06T16:08:31.396788+00:00",
              "published_date": null,
              "source_hash": "8d4d7cf189954e5b6ab2555ac027cf52"
            },
            {
              "url": "",
              "title": "Dyne Therapeutics Reports Second Quarter 2024 Financial Results and ...",
              "snippet": "In addition to the clinical update in May 2024, the Company also noted that based on recent dialogue with the Center for Drug Evaluation and Research (CDER) division of the U.S. Food and Drug Administration (FDA), Dyne continues to pursue an accelerated approval pathway for DYNE-101 in DM1, including leveraging splicing as a potential surrogate ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Dyne Therapeutics Inc Dyne Therapeutics Inc regulatory approval delays",
              "retrieved_at": "2025-01-06T16:08:31.396799+00:00",
              "published_date": null,
              "source_hash": "d67925d557854d5d67fbcd5ac9fc752f"
            },
            {
              "url": "",
              "title": "DYN SEC Filings - Dyne Therapeutics, Inc.- Annual Report ... - Fintel",
              "snippet": "DYN / Dyne Therapeutics, Inc. - SEC Filings, Annual Report, Proxy Statement ... EX-99.1 2 v427372ex-1.htm EXHIBIT 1 Exhibit 1 POWER OF ATTORNEY FOR CERTAIN REGULATORY FILINGS INCLUDING CERTAIN FILINGS UNDER THE SECURITIES EXCHANGE ACT OF 1934 AND THE INVESTMENT ADVISERS ACT OF 1940 I, David E. Shaw, hereby make, constitute, and appoint each of ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Dyne Therapeutics Inc Dyne Therapeutics Inc regulatory approval delays",
              "retrieved_at": "2025-01-06T16:08:31.396810+00:00",
              "published_date": null,
              "source_hash": "fd31f2b1182494f5546da13ec3252ee3"
            },
            {
              "url": "",
              "title": "Dyne Therapeutics Reports Third Quarter 2024 Financial Results and ...",
              "snippet": "The Company continues to pursue expedited approval pathways for DYNE-251, including accelerated approval in the U.S. based on dystrophin as a surrogate endpoint. Third Quarter 2024 Financial Results",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Dyne Therapeutics Inc Dyne Therapeutics Inc regulatory approval delays",
              "retrieved_at": "2025-01-06T16:08:31.396819+00:00",
              "published_date": null,
              "source_hash": "0028bb7d837cf95cad179bef5a9b12c7"
            },
            {
              "url": "",
              "title": "Director, Regulatory Affairs CMC - Dyne Therapeutics",
              "snippet": "Company Overview: Dyne Therapeutics is a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases. With its proprietary FORCE\u2122 platform, Dyne is developing modern oligonucleotide therapeutics that are designed to overcome limitations in delivery to muscle tissue. Dyne has a broad pipeline for ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Dyne Therapeutics Inc Dyne Therapeutics Inc regulatory approval delays",
              "retrieved_at": "2025-01-06T16:08:31.396828+00:00",
              "published_date": null,
              "source_hash": "f520d62c011e267c1decac130f474d93"
            },
            {
              "url": "",
              "title": "Dyne Therapeutics Inc. (DYN): Among the NASDAQ Stocks with Biggest Upside Potential According to Analysts",
              "snippet": "In this article, we are going to take a look at where Dyne Therapeutics Inc ... approval processes for both DYNE-101 and DYNE-251. Despite challenges, with positive clinical data and regulatory ...",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Dyne Therapeutics Inc Dyne Therapeutics Inc regulatory approval delays",
              "retrieved_at": "2025-01-06T16:08:33.855050+00:00",
              "published_date": "2024-11-22T11:56:00+00:00",
              "source_hash": "22243ee7b0cd4e6b242e2242a53de169"
            },
            {
              "url": "",
              "title": "Dyne Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update",
              "snippet": "Nov. 12, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc ... approval pathways for DYNE-101 and DYNE-251, expectations regarding the timing and outcome of interactions with global regulatory ...",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Dyne Therapeutics Inc Dyne Therapeutics Inc regulatory approval delays",
              "retrieved_at": "2025-01-06T16:08:33.855153+00:00",
              "published_date": "2024-11-12T12:30:00+00:00",
              "source_hash": "1a443c60d26a88fe2d722c0936005f73"
            },
            {
              "url": "",
              "title": "Genetic Medicines Biotech Dyne Pulls In $345M for Clinical Tests of Muscle Drugs",
              "snippet": "Dyne Therapeutics started ... of patients that could support regulatory submissions for the respective therapies. \"I think that our pathway to a regulatory approval globally is more validated ...",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Dyne Therapeutics Inc Dyne Therapeutics Inc regulatory approval delays",
              "retrieved_at": "2025-01-06T16:08:33.855185+00:00",
              "published_date": "2024-01-15T00:00:00+00:00",
              "source_hash": "73df579e520c8fb045ffa3a7fa81d668"
            },
            {
              "url": "",
              "title": "Why Did Dyne Therapeutics Inc (DYN) Plummet? Key Factors Explained",
              "snippet": "In terms of valuation, Dyne Therapeutics Inc's market capitalization stands at $2.40 billion. Market cap represents the total value of all outstanding shares and is a key indicator of a company's market value. Additionally, the Price-to-Book Ratio is 3.4, comparing the market value to the company's book value.",
              "domain": "",
              "source_type": "news",
              "category": "ethical_social",
              "query_context": "Dyne Therapeutics Inc Dyne Therapeutics Inc patient advocacy controversies",
              "retrieved_at": "2025-01-06T16:08:37.842537+00:00",
              "published_date": "2025-01-01T13:26:00+00:00",
              "source_hash": "c91f01ac4528b3bb744a71fcc0c1b539"
            },
            {
              "url": "",
              "title": "Promising Developments at Dyne Therapeutics: Analyst Recommends 'Buy' Based on DYNE-101 and '251 Program Progress",
              "snippet": "The favorable dystrophin expression data, especially at the 20 mg/kg dose, supports the potential for accelerated approval ... Dyne Therapeutics (DYN) Company Description: Dyne Therapeutics Inc ...",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Dyne Therapeutics Inc Dyne Therapeutics Inc regulatory approval delays",
              "retrieved_at": "2025-01-06T16:08:33.855235+00:00",
              "published_date": "2024-11-13T05:35:00+00:00",
              "source_hash": "eb4714425c369e95e3e4fc179057e1ba"
            },
            {
              "url": "",
              "title": "DELIVER FAQ - Dyne Therapeutics",
              "snippet": "It is publicly available on our website and has been shared at multiple Patient Advocacy Organization events. For more information: ... Questions for Dyne Therapeutics can be directed to clinicaltrials@dyne-tx.com. Updated November 2024. Stay in touch info@dyne-tx.com 781.786.8230;",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Dyne Therapeutics Inc Dyne Therapeutics Inc patient advocacy controversies",
              "retrieved_at": "2025-01-06T16:08:35.288975+00:00",
              "published_date": null,
              "source_hash": "322546a21079fe527e12ba72ad659d4e"
            },
            {
              "url": "",
              "title": "Dyne Therapeutics Announces FDA Clearance of IND Application ... - Nasdaq",
              "snippet": "--Dyne Therapeutics, Inc., ... patient advocacy groups and individuals living with DMD to thoughtfully design and execute our global multiple-ascending dose Phase 1/2 clinical trial of DYNE-251 ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Dyne Therapeutics Inc Dyne Therapeutics Inc patient advocacy controversies",
              "retrieved_at": "2025-01-06T16:08:35.289081+00:00",
              "published_date": null,
              "source_hash": "df3c7ca83acdd2af61e516bf16bb227b"
            },
            {
              "url": "",
              "title": "Dyne Therapeutics Announces Positive New Clinical Data from Phase 1/2 ...",
              "snippet": "Dyne Therapeutics, Inc. has announced positive new clinical data from its ongoing Phase 1/2 DELIVER trial of DYNE-251 in patients with Duchenne who are amenable to exon 51 skipping. DYNE-251 is an exon skipping product that combines a PMO to enable skipping of exon 51 with a fragment antibody (Fab) to increase targeted delivery of the drug to muscle.",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Dyne Therapeutics Inc Dyne Therapeutics Inc patient advocacy controversies",
              "retrieved_at": "2025-01-06T16:08:35.289095+00:00",
              "published_date": null,
              "source_hash": "f5b4aad507e44950b97fa171f9eb300a"
            },
            {
              "url": "",
              "title": "Clinical Trials - Dyne Therapeutics",
              "snippet": "Dyne Therapeutics is focused on advancing innovative, potentially life-transforming therapeutics for people living with genetically driven muscle diseases. Clinical trials, a type of research that studies the safety and efficacy of potential therapeutics in people, must be conducted before bringing new medicines to patients.",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Dyne Therapeutics Inc Dyne Therapeutics Inc patient advocacy controversies",
              "retrieved_at": "2025-01-06T16:08:35.289108+00:00",
              "published_date": null,
              "source_hash": "6a7bd7e723e7b88ecdfef9bcb3924fd9"
            },
            {
              "url": "",
              "title": "Dyne Therapeutics Announces FDA Clearance of IND Application for DYNE ...",
              "snippet": "- Initiation of Dosing in Multiple Ascending Dose Clinical Trial in Patients with Mutations Amenable to Skipping Exon 51 On Track for Mid-2022 - WALTHAM, Mass., July 05, 2022 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Dyne Therapeutics Inc Dyne Therapeutics Inc patient advocacy controversies",
              "retrieved_at": "2025-01-06T16:08:35.289117+00:00",
              "published_date": null,
              "source_hash": "3b43f7420f3bd6395a7a17e1b2253679"
            },
            {
              "url": "",
              "title": "Dyne Therapeutics Announces FDA Clearance of IND Application for DYNE ...",
              "snippet": "Dyne Therapeutics, Inc. - Initiation of Dosing in Multiple Ascending Dose Clinical Trial in Patients with Mutations Amenable to Skipping Exon 51 On Track for Mid-2022 -",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Dyne Therapeutics Inc Dyne Therapeutics Inc patient advocacy controversies",
              "retrieved_at": "2025-01-06T16:08:35.289151+00:00",
              "published_date": null,
              "source_hash": "5a9b6025cd02c0a9fcea78baa9c475c2"
            },
            {
              "url": "",
              "title": "Dyne Therapeutics Announces FDA Clinical Hold on IND Application for ...",
              "snippet": "WALTHAM, Mass., Jan. 18, 2022 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a muscle disease company focused on advancing innovative life-transforming therapeutics for people living ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Dyne Therapeutics Inc Dyne Therapeutics Inc patient advocacy controversies",
              "retrieved_at": "2025-01-06T16:08:35.289160+00:00",
              "published_date": null,
              "source_hash": "0f96a25183ce568d47adfa45a7367d87"
            },
            {
              "url": "",
              "title": "Dyne Therapeutics, Inc. - Drug pipelines, Patents, Clinical ... - Patsnap",
              "snippet": "- Presentations Will Feature Recent Clinical Data From DYNE-251 and DYNE-101 as Well as Preclinical Data in FSHD and Pompe Disease - WALTHAM, Mass., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Dyne Therapeutics Inc Dyne Therapeutics Inc patient advocacy controversies",
              "retrieved_at": "2025-01-06T16:08:35.289168+00:00",
              "published_date": null,
              "source_hash": "b87894368699822d937d693b7c4a7ff3"
            },
            {
              "url": "",
              "title": "Dyne Therapeutics Inc. (DYN): Among the NASDAQ Stocks with Biggest Upside Potential According to Analysts",
              "snippet": "In this article, we are going to take a look at where Dyne Therapeutics Inc. (NASDAQ ... efficacy, and patient-reported outcomes, is expected in early January 2025. This data will inform the ...",
              "domain": "",
              "source_type": "news",
              "category": "ethical_social",
              "query_context": "Dyne Therapeutics Inc Dyne Therapeutics Inc patient advocacy controversies",
              "retrieved_at": "2025-01-06T16:08:37.842487+00:00",
              "published_date": "2024-11-22T11:56:00+00:00",
              "source_hash": "2427ff3c6b974882b4a04cc09f20690d"
            },
            {
              "url": "",
              "title": "Why Is Rare Muscle Disease-Focused Dyne Therapeutics Stock Soaring Today?",
              "snippet": "Dyne Therapeutics Inc (NASDAQ: DYN) released initial clinical data from its ACHIEVE trial of DYNE-101 in patients with myotonic dystrophy type 1 (DM1) and its DELIVER trial of DYNE-251 in patients ...",
              "domain": "",
              "source_type": "news",
              "category": "ethical_social",
              "query_context": "Dyne Therapeutics Inc Dyne Therapeutics Inc patient advocacy controversies",
              "retrieved_at": "2025-01-06T16:08:37.842525+00:00",
              "published_date": "2024-01-03T14:18:00+00:00",
              "source_hash": "7e9de70c7275455bee044894bda8fb73"
            },
            {
              "url": "",
              "title": "Promising Developments at Dyne Therapeutics: Analyst Recommends 'Buy' Based on DYNE-101 and '251 Program Progress",
              "snippet": "Dyne Therapeutics (DYN) Company Description: Dyne Therapeutics Inc is a bio-technology company focused on providing therapeutics for patients with genetically driven diseases. The company is ...",
              "domain": "",
              "source_type": "news",
              "category": "ethical_social",
              "query_context": "Dyne Therapeutics Inc Dyne Therapeutics Inc patient advocacy controversies",
              "retrieved_at": "2025-01-06T16:08:37.842548+00:00",
              "published_date": "2024-11-13T05:35:00+00:00",
              "source_hash": "12425f38f80591c863f5f6a9ed9b71f7"
            },
            {
              "url": "",
              "title": "Dyne Therapeutics Reveals Q3 Results and Trial Updates",
              "snippet": "Dyne Therapeutics, Inc. ( (DYN)) has released its Q3 earnings. Here is a breakdown of the information Dyne Therapeutics, Inc. presented to its investors. Dyne Therapeutics, Inc. is a clinical ...",
              "domain": "",
              "source_type": "news",
              "category": "ethical_social",
              "query_context": "Dyne Therapeutics Inc Dyne Therapeutics Inc patient advocacy controversies",
              "retrieved_at": "2025-01-06T16:08:37.842556+00:00",
              "published_date": "2024-11-14T08:45:00+00:00",
              "source_hash": "2e8185fbd18f952e45571f3824842d97"
            }
          ],
          "queries": [
            {
              "category": "financial_legal",
              "query": "Dyne Therapeutics Inc clinical trial failures",
              "rationale": "Investigate potential risks related to the efficacy and safety of Dyne's therapeutic candidates in clinical trials",
              "priority": 1
            },
            {
              "category": "financial_legal",
              "query": "Dyne Therapeutics Inc regulatory approval delays",
              "rationale": "Examine potential delays or rejections by regulatory agencies that could impact Dyne's business prospects",
              "priority": 2
            },
            {
              "category": "ethical_social",
              "query": "Dyne Therapeutics Inc patient advocacy controversies",
              "rationale": "Assess any ethical or social concerns related to patient advocacy or treatment access for rare muscle diseases",
              "priority": 3
            }
          ]
        },
        "categorization": {
          "product_issues": [],
          "conduct_issues": [],
          "tags": [],
          "patterns": {}
        }
      },
      "metadata": {
        "analysis_timestamp": "2025-01-06T09:08:56.598287",
        "data_confidence": 80,
        "pattern_confidence": null
      }
    }
  ]
}